BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28383573)

  • 1. CORRIGENDUM: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Genet Med; 2017 Apr; 19(4):484. PubMed ID: 28383573
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
    Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2022 Jul; 24(7):1407-1414. PubMed ID: 35802134
    [No Abstract]   [Full Text] [Related]  

  • 4. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2023 Aug; 25(8):100866. PubMed ID: 37347242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Chung WK; Gordon AS; Herman GE; Klein TE; Stewart DR; Amendola LM; Adelman K; Bale SJ; Gollob MH; Harrison SM; Hershberger RE; McKelvey K; Richards CS; Vlangos CN; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1381-1390. PubMed ID: 34012068
    [No Abstract]   [Full Text] [Related]  

  • 6. Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al.
    McGurk KA; Zheng SL; Henry A; Josephs K; Edwards M; de Marvao A; Whiffin N; Roberts A; Lumbers TR; O'Regan DP; Ware JS
    Genet Med; 2022 Mar; 24(3):744-746. PubMed ID: 34906520
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Gordon AS; Amendola LM; Adelman K; Bale SJ; Chung WK; Gollob MH; Harrison SM; Herman GE; Hershberger RE; Klein TE; McKelvey K; Richards CS; Vlangos CN; Stewart DR; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1391-1398. PubMed ID: 34012069
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    ACMG Board of Directors
    Genet Med; 2019 Jul; 21(7):1467-1468. PubMed ID: 31019278
    [No Abstract]   [Full Text] [Related]  

  • 9. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    Green RC; Berg JS; Grody WW; Kalia SS; Korf BR; Martin CL; McGuire AL; Nussbaum RL; O'Daniel JM; Ormond KE; Rehm HL; Watson MS; Williams MS; Biesecker LG;
    Genet Med; 2013 Jul; 15(7):565-74. PubMed ID: 23788249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Gordon AS; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Harrison SM; Hershberger RE; Richards CS; Stewart DR; Martin CL; Miller DT;
    Genet Med; 2024 May; ():101142. PubMed ID: 38819344
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to "The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG)".
    Nussbaum RL; Haverfield E; Esplin ED; Aradhya S
    Genet Med; 2019 Dec; 21(12):2836-2837. PubMed ID: 31239557
    [No Abstract]   [Full Text] [Related]  

  • 13. Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.
    Huang Y; Liu B; Shi J; Zhao S; Xu K; Sun L; Chen N; Tian W; Zhang J; Wu N
    J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting Incidental Findings in Clinical Whole Exome Sequencing: Incorporation of the 2013 ACMG Recommendations into Current Practices of Genetic Counseling.
    Smith LA; Douglas J; Braxton AA; Kramer K
    J Genet Couns; 2015 Aug; 24(4):654-62. PubMed ID: 25403901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing.
    Evans BJ
    Genet Med; 2013 Dec; 15(12):915-20. PubMed ID: 24030435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    Li MM; Chao E; Esplin ED; Miller DT; Nathanson KL; Plon SE; Scheuner MT; Stewart DR;
    Genet Med; 2020 Jul; 22(7):1142-1148. PubMed ID: 32321997
    [No Abstract]   [Full Text] [Related]  

  • 17. Points to consider in the practice of postmortem genetic testing: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Deignan JL; De Castro M; Horner VL; Johnston T; Macaya D; Maleszewski JJ; Reddi HV; Tayeh MK;
    Genet Med; 2023 May; 25(5):100017. PubMed ID: 36799919
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding variations in secondary findings reporting practices across U.S. genome sequencing laboratories.
    Ackerman SL; Koenig BA
    AJOB Empir Bioeth; 2018; 9(1):48-57. PubMed ID: 29131714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).
    Rehder C; Bean LJH; Bick D; Chao E; Chung W; Das S; O'Daniel J; Rehm H; Shashi V; Vincent LM;
    Genet Med; 2021 Aug; 23(8):1399-1415. PubMed ID: 33927380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
    Bush LW; Bartoshesky LE; David KL; Wilfond B; Williams JL; Holm IA;
    Genet Med; 2018 Jul; 20(7):692-694. PubMed ID: 29565417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.